ERBB2 and neoplasm: This short-term treatment led to a significant reduction in tumor incidence: by 3 months post ErbB2 activation, only three of the eight C188-9-treated mice had developed palpable tumors, while all 10 diluent-treated parous mice had done so (Figure 6J).